A Prospective, Multicenter, Open label, non-Randomized, noninterventional,real world, Observational Registry Study to collecteffectiveness and safety data of ULIHOPE (Ulinastatin) along with thestandard therapy (antibiotics) & supportive care in the managementof Sepsis in Indian Patients. (PRO-ULIHOPE Study: Patient Registryof ULIHOPE) - PRO-ULIHOPE

RIHK Pharmaceutical Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. A written signed and dated data sharing informed consent from subjects or legally
•acceptable representative.
•2. Either gender of age between 18 and 65 years (both inclusive).
•3. Subjects with diagnosis of Sepsis.

•1. Subjects with hypersensitivity to Ulinastatin or any of its components.
•2. Subjects who are pregnant or breast feeding.
•3. Subjects with do-not-resuscitation order.
•4. Subjects transferred to hospital/nursing home at late stage of Sepsis.
•5. Subject with any other condition not suitable to participate as per treating Physicianâ??s discretion.

发起方

RIHK Pharmaceutical Pvt Ltd